AntalGenics is a biotechnological company focused on the discovery and development of new bioactive molecules for biomedical and dermocosmetic applications
AntalGenics is a biotechnological company focused on the discovery and development of new bioactive molecules for biomedical and dermocosmetic applications
DISCOVERY
AntalGenics focuses its R&D program on the discovery, validation and development of bioactive molecules for biomedicine and dermocosmetic area.
QUALITY
AntalGenics aims is to become a quality reference in the development and commercialisation of bioactive topical applications.
INTERMEDIATION
AntalGenics acts as an intermediator and translator between the research world and the productive sector.
AntalGenics’ R&D programme is located in the last research stage, the translation into the society, transforming its scientific results and technology into fully exploitable products or services for third parties.
licensed cosmeceutical products currently on the market
patents of new analgesic and cosmetic molecules
years of experience
MISSION
To discover and develop innovative analgesic leads in the field of sensory neurobiology and pain transduction.
VISION
To generate precise, novel analgesic therapeutics for the treatment of pain, inflammatory skin disorders and sensitive skin.
STRATEGY
To develop internal R&D projects with validated targets by focusing on peripheral mechanisms and topical treatments.
To license out leads upon Phase II/III clinical trials.
To license in novel technologies from public research.
To offer to third parties specifically tailored R&D projects with the possibility of generating intellectual property rights.
Founded in February 2015, AntalGenics is located in the Scientific Park of the University Miguel Hernández in Elche, Alicante, Spain